arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Coya Therapeutics, Inc.

COYA
$5.05 ▼ -0.25 (-4.81%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Coya Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $118.5M
Dividend Yield —
Revenue Growth 49.0% ↗
Op. Margin None
ROIC -12.9% ↘
FCF / Share $-0.31 ↘
Trailing P/E —
Price / Book 2.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

20-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$243.75K
↑ +49.0% —
Net Income Profit after all expenses
$-7.21M
↑ +1.4% —
Operating Margin Operating profit as % of sales
-152.3%
↓ -123.1% 0th
FCF / Share Free cash flow per share
$-0.31
↓ -14.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↑
17
Cash Quality ↓
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 20 quarters